Transition of Leadership at the American Cancer Society
The American Cancer Society (ACS) announces that CEO Karen E. Knudsen, MBA, PhD, will transition from her role at ACS and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN).
This decision comes as part of her strategy to accelerate progress against cancer after a transformative tenure since 2021.
Under Dr. Knudsen’s leadership, ACS has seen remarkable achievements, including a more than 30% increase in annual revenue and the organization’s first-ever highest rating from Charity Navigator.
Her vision modernized the mission, focusing on improving the lives of cancer patients and their families while successfully transitioning ACS into a unified, high-performing organization.
The ACS Board of Directors will appoint an interim CEO before the end of the year and will commence a national search for her successor.
Dr. Knudsen has graciously agreed to remain as an Executive Strategic Advisor through early 2025 to ensure a smooth transition.
‘Dr. Knudsen has been a trailblazer in every sense,’ said Brian Marlow, Chair of the ACS Board.
‘Her leadership has transformed ACS into a more impactful organization, and we are deeply grateful for her dedication to the cancer community.’
Notable accomplishments during Dr. Knudsen’s tenure include the establishment of the organization’s first Chief Diversity Officer, significant expansion of cancer research funding (with over $465 million currently committed), and the creation of the ACS Patient Support Pillar to address the logistical needs of cancer patients.
Additionally, she led policy efforts that increased access to quality cancer prevention and care, achieving significant wins at both the federal and state levels.
Dr. Knudsen emphasized the importance of strategic partnerships and innovation during her time at ACS, launching initiatives such as BrightEdge, the impact investment arm, and collaborations aimed at increasing cancer screening uptake.
“I am incredibly proud of what we have achieved together, ACS is now poised to further increase its impact in solving the cancer problem, and I have every confidence in its future.” – Karen Knudsen
As the organization prepares for this transition, the ACS community remains focused on its mission to improve lives and advance the fight against cancer.
For more posts like this, visit oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023